March 18, 2026 19:34 ET | Source: Vaxcyte, Inc. Based on the Strength of Unprecedented Results from the Positive Phase…
HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated target in…
Prestigious recognition includes number one overall rank for the EMEA region BENGALURU, India, Oct. 3, 2025 /PRNewswire/ -- UST, a…
Safety endpoint met, with encouraging signs of efficacy in trial with 23 patients suffering from intracerebral hemorrhage (ICH)Findings suggest BIOX-101…
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused…